Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2019 1
2020 3
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean min ji yang (4 results)?
Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models.
Yang Y, Yang H, Alcaina Y, Puc J, Birt A, Vedvyas Y, Gallagher M, Alla S, Riascos MC, McCloskey JE, Du K, Gonzalez-Valdivieso J, Min IM, de Stanchina E, Britz M, von Hofe E, Jin MM. Yang Y, et al. Among authors: min im. Nat Commun. 2023 Apr 12;14(1):2068. doi: 10.1038/s41467-023-37646-y. Nat Commun. 2023. PMID: 37045815 Free PMC article.
Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Limberg J, Egan CE, Gray KD, Singh M, Loewenstein Z, Yang Y, Riascos MC, Al Asadi H, Safe P, El Eshaky S, Liang H, Ullmann TM, Wang W, Li W, Zhang T, Xiang J, Stefanova D, Jin MM, Zarnegar R, Fahey TJ, Min IM. Limberg J, et al. Among authors: min im. Mol Cancer Res. 2023 May 1;21(5):397-410. doi: 10.1158/1541-7786.MCR-21-0832. Mol Cancer Res. 2023. PMID: 36790391 Free PMC article.
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, Stefanova D, Christos PJ, Scognamiglio T, Tassler AB, Zarnegar R, Fahey TJ 3rd, Jin MM, Min IM. Gray KD, et al. Among authors: min im. Clin Cancer Res. 2020 Nov 15;26(22):6003-6016. doi: 10.1158/1078-0432.CCR-20-1523. Epub 2020 Sep 4. Clin Cancer Res. 2020. PMID: 32887724 Free PMC article.
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.
Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, Jin MM. Jung M, et al. Among authors: min im. Mol Ther Oncolytics. 2020 Aug 21;18:587-601. doi: 10.1016/j.omto.2020.08.009. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32995483 Free PMC article.
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y, McCloskey JE, Yang H, Puc J, Alcaina Y, Vedvyas Y, Gomez Gallegos AA, Ortiz-Sánchez E, de Stanchina E, Min IM, von Hofe E, Jin MM. Yang Y, et al. Among authors: min im. Cancer Immunol Res. 2021 Oct;9(10):1158-1174. doi: 10.1158/2326-6066.CIR-21-0062. Epub 2021 Aug 2. Cancer Immunol Res. 2021. PMID: 34341066 Free PMC article.
13 results